COVID-19 and multiple sclerosis: challenges and lessons for patient care

IF 13.6 Q1 HEALTH CARE SCIENCES & SERVICES
Luca Prosperini , Georgina Arrambide , Elisabeth G. Celius , Delia Goletti , Joep Killestein , Daphne Kos , Luigi Lavorgna , Celine Louapre , Maria Pia Sormani , Dominika Stastna , Tjalf Ziemssen , Massimiliano Di Filippo
{"title":"COVID-19 and multiple sclerosis: challenges and lessons for patient care","authors":"Luca Prosperini ,&nbsp;Georgina Arrambide ,&nbsp;Elisabeth G. Celius ,&nbsp;Delia Goletti ,&nbsp;Joep Killestein ,&nbsp;Daphne Kos ,&nbsp;Luigi Lavorgna ,&nbsp;Celine Louapre ,&nbsp;Maria Pia Sormani ,&nbsp;Dominika Stastna ,&nbsp;Tjalf Ziemssen ,&nbsp;Massimiliano Di Filippo","doi":"10.1016/j.lanepe.2024.100979","DOIUrl":null,"url":null,"abstract":"<div><p>During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of disease-modifying treatments (DMTs). Key concerns arose, primarily related to the possibility that SARS-CoV-2 infection could trigger the initial demyelinating event or exacerbate disease activity. Another major concern was the safety and efficacy of the COVID-19 vaccines, especially for patients undergoing specific treatments that could weaken their antibody responses. In the post-infection phase, identifying long COVID in patients with MS has been complicated due to the large overlap between post-infection sequelae and MS symptoms. In addition, disruptions in health and rehabilitation services have made it difficult for MS patients to access care. This Series article explores current evidence on the interaction between MS and SARS-CoV-2, identifies the challenges posed by the COVID-19 pandemic in the care of patients with MS, and discusses the significant adoption of digital health solutions, including telemedicine and new technology-based rehabilitation approaches. Based on lessons learned, recommendations and future directions are offered for managing patients with MS, rethinking healthcare systems and improving health outcomes in the post-COVID-19 pandemic era.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001467/pdfft?md5=5789b2ba7111b11da22d81b5b0a41423&pid=1-s2.0-S2666776224001467-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Europe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666776224001467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of disease-modifying treatments (DMTs). Key concerns arose, primarily related to the possibility that SARS-CoV-2 infection could trigger the initial demyelinating event or exacerbate disease activity. Another major concern was the safety and efficacy of the COVID-19 vaccines, especially for patients undergoing specific treatments that could weaken their antibody responses. In the post-infection phase, identifying long COVID in patients with MS has been complicated due to the large overlap between post-infection sequelae and MS symptoms. In addition, disruptions in health and rehabilitation services have made it difficult for MS patients to access care. This Series article explores current evidence on the interaction between MS and SARS-CoV-2, identifies the challenges posed by the COVID-19 pandemic in the care of patients with MS, and discusses the significant adoption of digital health solutions, including telemedicine and new technology-based rehabilitation approaches. Based on lessons learned, recommendations and future directions are offered for managing patients with MS, rethinking healthcare systems and improving health outcomes in the post-COVID-19 pandemic era.

COVID-19 与多发性硬化症:患者护理的挑战与经验
在 COVID-19 大流行期间,多发性硬化症(MS)患者及其医疗服务提供者面临着与 SARS-CoV-2、潜在神经系统疾病和使用疾病改变疗法(DMTs)之间相互作用有关的独特挑战。其中出现的主要问题是,SARS-CoV-2 感染可能引发最初的脱髓鞘事件或加剧疾病活动。另一个主要问题是 COVID-19 疫苗的安全性和有效性,尤其是正在接受特定治疗的患者,因为这些治疗可能会削弱他们的抗体反应。在感染后阶段,由于感染后遗症和多发性硬化症症状之间存在大量重叠,因此在多发性硬化症患者中识别长 COVID 变得非常复杂。此外,医疗和康复服务的中断也使多发性硬化症患者难以获得治疗。本系列文章探讨了多发性硬化症与 SARS-CoV-2 之间相互作用的现有证据,明确了 COVID-19 大流行给多发性硬化症患者护理带来的挑战,并讨论了数字医疗解决方案的大量采用,包括远程医疗和基于新技术的康复方法。在总结经验教训的基础上,提出了在后 COVID-19 大流行时代管理多发性硬化症患者、重新思考医疗保健系统和改善健康结果的建议和未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
19.90
自引率
1.40%
发文量
260
审稿时长
9 weeks
期刊介绍: The Lancet Regional Health – Europe, a gold open access journal, is part of The Lancet's global effort to promote healthcare quality and accessibility worldwide. It focuses on advancing clinical practice and health policy in the European region to enhance health outcomes. The journal publishes high-quality original research advocating changes in clinical practice and health policy. It also includes reviews, commentaries, and opinion pieces on regional health topics, such as infection and disease prevention, healthy aging, and reducing health disparities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信